Ibrexafungerp Citrate
FDA-approved product (tablet, oral), marketed as Brexafemme.
- Registered studies
- 0
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Vulvovaginal candidiasis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antimycotics for systemic use
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AX07
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA63.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae44.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis46.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
No evidence found
The registry was searched and no registered study names this medicine.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ibrexafungerp Citrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DarolutamideExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 4 more53.3% AI-predicted activityagainst MRSA50+ registered studies
- Loteprednol EtabonateExisting use: Allergic conjunctivitis, Anterior uveitis, Dry eye syndrome and 2 more53.2% AI-predicted activityagainst MRSA50+ registered studies
- TipranavirExisting use: Hemorrhage, HIV infection, Viral disease53.2% AI-predicted activityagainst MRSA50+ registered studies
- PimozideExisting use: Psychosis, Tics, Tourette syndrome53.2% AI-predicted activityagainst MRSA15 registered studies
- Triamcinolone HexacetonideExisting use: Airway obstruction, Eye inflammation, Hemorrhoid and 3 more53.1% AI-predicted activityagainst MRSA50+ registered studies
- Daridorexant HydrochlorideExisting use: Insomnia53.1% AI-predicted activityagainst MRSA2 registered studies
- Tafenoquine SuccinateExisting use: Malaria, Plasmodium vivax malaria53.1% AI-predicted activityagainst MRSA42 registered studies
- Lenvatinib MesylateExisting use: Cancer, Neoplasm, Papillary thyroid carcinoma and 4 more53.0% AI-predicted activityagainst MRSA23 registered studies
- ZanubrutinibExisting use: Cancer, Mantle cell lymphoma, Neoplasm and 1 more53.0% AI-predicted activityagainst MRSA50+ registered studies
- Ritlecitinib TosylateExisting use: Alopecia areata52.8% AI-predicted activityagainst MRSA1 registered study
- Raloxifene HydrochlorideExisting use: Breast cancer, Osteoporosis, Postmenopausal osteoporosis52.7% AI-predicted activityagainst MRSA50+ registered studies
- Neratinib MaleateExisting use: Breast cancer, Breast carcinoma, Breast neoplasm52.7% AI-predicted activityagainst MRSA7 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
No evidence found: the registry was searched and no registered study names this medicine.